AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUTEP LTD

0.240

+0.0052.13%

Volume:657.59K

Turnover:157.14K

Market Cap:349.34M

PE:-7.30

High:0.245

Open:0.235

Low:0.235

Close:0.235

Loading ...

Overview Company News Filings

Immutep to Participate in Upcoming Investor Conferences

First Patient Dosed in Immutep’s Tacti-004 Phase Iii Trial in First Line Non-Small Cell Lung Cancer

THOMSON REUTERS

Immutep notches upward on first lung cancer patient dosing

The Market Herald

Immutep Doses First Patient in Phase 3 Trial of Non-Small Cell Lung Cancer Combination Therapy Candidate

MT Newswires Live

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

Great week for Immutep Limited (ASX:IMM) institutional investors after losing 16% over the previous year

Simply Wall St.

Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?

Immutep Quarterly Activities Report Q2 FY25

Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?

Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?

Patient Enrolment Completed for Eftisarc-Neo Phase Ii Trial

THOMSON REUTERS

Immutep Ltd - Data Updates From Eftisarc-Neo Expected in 2025

THOMSON REUTERS

Immutep Completes Patient Enrolment for Phase Two Trial For Soft Tissue Sarcoma Treatment

MT Newswires Live

Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company

Simply Wall St.

BRIEF-Immutep Completes Patient Enrolment For INSIGHT-003

Immutep Ltd: Data Updates From Insight-003 Are Expected in 2025 and Beyond

THOMSON REUTERS

Immutep Ltd: Patient Enrolment Completed for Insight-003

THOMSON REUTERS

Patient Enrolment Completed for INSIGHT-003

Immutep Reaches Enrollment Target for Non-Small Cell Lung Cancer Therapy Trial

MT Newswires Live

BRIEF-Immutep Announces Initial Safety Data From First-In-Human Phase I Trial Evaluating IMP761

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.24,"timestamp":1745296522206,"preClose":0.235,"halted":0,"volume":657591,"delay":0,"nameEN":"IMMUTEP LTD","floatShares":1247645358,"shares":1455589575,"eps":-0.032898,"marketStatus":"Trading","change":0.005,"latestTime":"04-22 14:45:11 AEST","open":0.235,"high":0.245,"low":0.235,"amount":157142,"amplitude":0.042553,"askPrice":0.245,"askSize":138357,"bidPrice":0.24,"bidSize":80088,"shortable":3,"etf":0,"ttmEps":-0.032898,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745301600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.235,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.437906,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1247645358,"roa":"-20.35%","roe":"-30.45%","lyrEps":-0.035565,"volumeRatio":0.437906,"shares":1455589575,"dividePrice":0,"high":0.245,"amplitude":0.042553,"preClose":0.235,"low":0.235,"week52Low":0.222,"pbRate":"2.03","psRate":"71.60","week52High":0.46,"institutionHeld":0,"latestPrice":0.24,"committee":-0.266744,"eps":-0.032898,"divideRate":0,"volume":657591,"delay":0,"ttmEps":-0.032898,"open":0.235,"prevYearClose":0.365,"prevWeekClose":0.235,"prevMonthClose":0.28,"prevQuarterClose":0.28,"fiveDayClose":0.24,"twentyDayClose":0.31,"sixtyDayClose":0.33},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524467908","title":"Immutep to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467908?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:00","pubTimestamp":1743595200,"startTime":"0","endTime":"0","summary":"SYDNEY, AUSTRALIA , April 02, 2025  -- Immutep Limited  , a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:. Additional information for the Jefferies presentationwill be made available closer to the conference on theEvents pagewithin the Investors & Media section of Immutep’s website.About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 , and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.U.S. Media:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-participate-upcoming-investor-conferences-120000160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4139","BK7508","BK7067","IMM.AU","IMMP"],"gpt_icon":0},{"id":"2522223070","title":"First Patient Dosed in Immutep’s Tacti-004 Phase Iii Trial in First Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522223070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522223070?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA13BLV1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2522105855","title":"Immutep notches upward on first lung cancer patient dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522105855","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522105855?lang=en_us&edition=fundamental","pubTime":"2025-03-25 08:17","pubTimestamp":1742861820,"startTime":"0","endTime":"0","summary":"Immutep Ltd  has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial – the final stage of clinical study before the company eventually takes final efficacy results to regulators.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.That’ll eventually include the FDA, given Immutep’s dual Australia-U.S. share listing, where the company sits on the NASDAQ.But first, the company needs to prove to Australia’s TGA its drugs are effective.“Trial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology,” the company said.Non-small cell lung cancer  is the most common type of lung cancer affecting the tissues of the organs themselves. Ultimately, all three dominant types of NSCLC are carcinomas.The material provided in this article is for information only and should not be treated as invest","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/immutep-notches-upward-on-first-lung-cancer-patient-dosing-2025-03-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2522082351","title":"Immutep Doses First Patient in Phase 3 Trial of Non-Small Cell Lung Cancer Combination Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522082351","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522082351?lang=en_us&edition=fundamental","pubTime":"2025-03-25 07:33","pubTimestamp":1742859198,"startTime":"0","endTime":"0","summary":"Immutep  has dosed the first patient in its TACTI-004 phase 3 trial evaluating a potential combination therapy for non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.The trial is assessing Immutep's eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with NYSE-listed Merck's Keytruda anti-PD-1 therapy and chemotherapy as first-line treatment for patients with advanced or metastatic non-small cell lung cancer, per the filing.The study's dual primary endpoints are progression-free survival and overall survival. Results will support a potential marketing approval application.The global trial will enroll 756 patients at more than 150 clinical sites in over 25 countries, the filing stated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0208291251.USD","IE00BFTCPJ56.SGD","LU1989772923.USD","LU0320765489.SGD","IMM.AU","LU1974910355.USD","LU1917777945.USD","SG9999001440.SGD","IE00BLSP4239.USD","BK4585","LU1066051225.USD","BK4550","LU2468319806.SGD","SG9999001176.SGD","LU1116320737.USD","LU2023250843.SGD","MRK","LU0320765646.SGD","LU1066051811.HKD","SG9999014542.SGD","BK4588","LU0965508806.USD","LU2361045086.USD","LU0265550946.USD","LU1023059063.AUD","LU1430594728.SGD","SG9999001176.USD","LU1585245621.USD","SG9999015341.SGD","LU1929549753.HKD","BK4534","LU1699723380.USD","IE00B1BXHZ80.USD","LU0106261372.USD","LU0985320562.USD","IE00B2B36J28.USD","IE0009355771.USD","BK4007","LU0965509010.AUD","IE0002141913.USD","LU0965509101.SGD","LU0965509283.SGD","LU2361044949.HKD","LU0070302665.USD","LU1061106388.HKD","SG9999015358.SGD","LU1983299246.USD","LU2361044865.SGD","SGXZ57979304.SGD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2520537844","title":"Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520537844","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520537844?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"SYDNEY, AUSTRALIA, March 20, 2025  -- Immutep Limited  , a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress  2025, taking place in Paris, France, from 26-29 March 2025.Immutep CSO, Frédéric Triebel, M.D., Ph.D, said, “We look forward to engaging with physicians in the lung cancer community at the ELCC conference to discuss our TACTI-004 Phase III study that is actively recruiting patients. Efti in combination with KEYTRUDA may change the treatment paradigm for patients with advanced or metastatic non-small cell lung cancer, irrespective of their PD-L1 expression, and we hope to see this registrational trial confirm the promising safety and efficacy achieved to date.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-present-pivotal-tacti-004-120000117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","LU1035773651.USD","IMMP","PRGS","SG9999015358.SGD","LU0266013472.USD","SG9999002232.USD","LU0070302665.USD","LU1201861249.SGD","LU2065732104.USD","LU1023059063.AUD","LU1037948541.HKD","LU1934455863.HKD","LU2420271590.USD","LU1941712264.USD","SG9999014559.SGD","LU2237443978.SGD","LU1791807156.HKD","LU0077335932.USD","LU0238689110.USD","IE00B2B36J28.USD","BK4559","SG9999001176.SGD","LU2023250843.SGD","LU1061106388.HKD","BK4504","MRK","LU1668664300.SGD","IMM.AU","LU0265550359.USD","LU0861579265.USD","APC","BK4566","LU0058720904.USD","LU1066053197.SGD","LU0157215616.USD","LU1037948897.HKD","LU2023250504.SGD","LU2417539215.USD","IE00B4R5TH58.HKD","BK4585","LU1983299246.USD","BK4139","LU0106261372.USD","LU1934455277.USD","LU0320765646.SGD","LU1571399168.USD","IE00BLSP4239.USD","BK4550","LU0965509101.SGD","BK4516"],"gpt_icon":0},{"id":"2520148166","title":"Great week for Immutep Limited (ASX:IMM) institutional investors after losing 16% over the previous year","url":"https://stock-news.laohu8.com/highlight/detail?id=2520148166","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520148166?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:14","pubTimestamp":1742415253,"startTime":"0","endTime":"0","summary":"Key Insights Given the large stake in the stock by institutions, Immutep's stock price might be vulnerable to their...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/great-week-for-immutep-limited-asximm-institutional-investor","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK4139","BK7067","IMMP","IMM.AU"],"gpt_icon":0},{"id":"2510332348","title":"Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332348","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510332348?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:55","pubTimestamp":1739292914,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now.In this article, we are going to take a look at where Immutep Limited  stands against the other long term ASX stocks.Vanguard believes that Australia's economy remains well-placed to recover gradually in 2025 after the broader economy witnessed its slowest growth in 32 years in 2024 amid sticky inflation and higher interest rates. The investment firm expects modest improvement in economic momentum, courtesy of higher real household incomes as inflation subsides. Furthermore, a rebounding housing market and expectations of rate cuts might also provide some support.Key Indicators Likely to Shape Australia's Economy in 2025. The Reserve Bank of Australia  kept the policy rate target unchanged at 4.35% on December 10. However, the bank noted that it continues to see signs of inflation moving sustainably towards the target. That being said, Vanguard expects that RBA will remain patient and that a tight labor market i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-limited-immp-best-long-165514394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","LU1303367103.USD","USJW.SI","USAW.SI","RBA","NQmain",".IXIC","LU1815336091.USD","TQQQ","QLD","BK4137","NVIW.SI","SQQQ","OS","IMM.AU","BK4097","QID","BK4139","MNQmain","LU2098885051.SGD","PSQ","LU0757428866.USD","IMMP"],"gpt_icon":1},{"id":"2507957164","title":"Immutep Quarterly Activities Report Q2 FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957164","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957164?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer  received first regulatory approval. Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival  and 81.0% 24-month OS rate, significantly outperforming historical controls. Promising new results in first line head & neck cancer with PD-L1 CPS <1 reported at ESMO IO 2024, with median OS not reached and 67% 12-month OS rate well above historical controls. Phase II in soft tissue sarcoma shows three-fold increase in tumour hyalinization  compared to historical data from radiotherapy. Phase I trial of IMP761 reported favourable initial safety results advancing the first-in-class agonist LAG-3 antibody program. TACTI-004 – Start of Phase III Trial in 1L NSCLCIn December 2024, Immutep initiated its pivotal TACTI-004 Phase III clinical trial of eftilagimod alfa  for the treatment of first-line metastatic non-small cell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-quarterly-activities-report-q2-130000670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","ORR","INAQU","BK4139","BK4563","PFS","CTOS","IMM.AU","BK4097","BK4179","BK4195","IO","IMMP","BK4211","BK4104"],"gpt_icon":0},{"id":"2507952614","title":"Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507952614","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507952614?lang=en_us&edition=fundamental","pubTime":"2025-01-31 20:30","pubTimestamp":1738326649,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds.In this article, we are going to take a look at where Immutep Limited  stands against other best ASX stocks to buy according to hedge funds.According to a report by the Australian Bureau of Statistics  published on December 4, 2024, the Australian economy grew by 0.3% in the September quarter of 2024, which marked the twelfth consecutive quarter of growth. This growth, however, was the lowest rate since the December quarter of 2020 after the COVID-19 pandemic. The report also noted that in nominal terms, GDP rose by 0.4%.In terms of trade, a key indicator of the economy’s international competitiveness fell by 2.5% in the quarter. This decline was primarily due to a 2.6% drop in export prices and was the third consecutive quarterly fall. The weakening in global bulk commodity demand, particularly from China, significantly affected the prices of metallurgical coal and iron ore. Import prices also fell s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-limited-immp-one-best-123049394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU1720051108.HKD","BK4504","BK7067","BK4588","IE00BKVL7J92.USD","LU0225283273.USD","LU1668664300.SGD","LU0106831901.USD","LU2357305700.SGD","BK4139","LU1989772840.SGD","MNQmain","IMM.AU","USJW.SI","LU1548497426.USD","BK4581","LU1363072403.SGD","XJO.AU","IMMP","LU2028103732.USD","LU0158827948.USD","NQmain","QLD","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU0971096721.USD","LU1720051017.SGD","LU2271345857.HKD","BK4127","BK4516",".IXIC","USAW.SI","LU0098860793.USD","PSQ","LU1162221912.USD","XAO.AU","TQQQ","LU1074936037.SGD","NVIW.SI","XKO.AU","BK7508","LU2089283258.USD","LU1732800096.USD","LU2089284900.SGD","LU0912757837.SGD","TSYW.SI","QID","LU0106261372.USD","SQQQ"],"gpt_icon":1},{"id":"2506737480","title":"Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506737480","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506737480?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:02","pubTimestamp":1737982939,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Australian Stocks to Buy Now.In this article, we are going to take a look at where Immutep Limited stands against other best Australian stock to buy now.According to a report by Vanguard published on January 24, Australia’s economy is expected to experience a gradual recovery in 2025, following its slowest growth in 32 years in 2024. The report forecasts an economic growth of 2% year over year by the end of 2025, with trimmed mean inflation, a core measure that excludes items at the extremes, expected to reach 2.5% year over year. However, the report notes that low productivity growth and higher unit labor costs will keep core inflation from falling sustainably to the midpoint of the Reserve Bank of Australia’s  2%–3% target range until later in 2025.Why do we care about what hedge funds do?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-immutep-immp-among-best-130219369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","IMMP","QID","LU0757428866.USD","PSQ",".IXIC","MNQmain","IMM.AU","LU1303367103.USD","USJW.SI","LU1815336091.USD","SQQQ","TQQQ","USAW.SI","BK4137","QLD","NVIW.SI","NQmain","RBA","LU2098885051.SGD","BK4139"],"gpt_icon":1},{"id":"2505974461","title":"Patient Enrolment Completed for Eftisarc-Neo Phase Ii Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505974461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505974461?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUAJ4G8N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2505744246","title":"Immutep Ltd - Data Updates From Eftisarc-Neo Expected in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505744246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505744246?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUAJ4G8N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2505730891","title":"Immutep Completes Patient Enrolment for Phase Two Trial For Soft Tissue Sarcoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2505730891","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505730891?lang=en_us&edition=fundamental","pubTime":"2025-01-22 08:49","pubTimestamp":1737506996,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) completed the enrolment target of 40 patients for the EFTISARC-NEO second phase trial in Warsaw, Poland, according to a Wednesday filing with the Australian bourse.The EFTISARC-NEO t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2503606609","title":"Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2503606609","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503606609?lang=en_us&edition=fundamental","pubTime":"2025-01-16 06:39","pubTimestamp":1736980786,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Immutep implies that they have significant influence over the company's share price. Ownership research along with  analyst forecasts data  help provide a good understanding of opportunities in a stock. To get a sense of who is truly in control of Immutep Limited , it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 51% ownership. Put another way, the group faces the maximum upside potential .Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future.Let's delve deeper into each type of owner of Immutep, beginning with the chart below.What Does The Institutional Ownership Tell Us About Immutep?ASX:IMM Earnings and Reve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-limited-asx-imm-largely-223946698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IMMP","BK7508","BK7067","IMM.AU","BK4139"],"gpt_icon":0},{"id":"2501844231","title":"BRIEF-Immutep Completes Patient Enrolment For INSIGHT-003","url":"https://stock-news.laohu8.com/highlight/detail?id=2501844231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501844231?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:15","pubTimestamp":1736169328,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Completes Patient Enrolment For INSIGHT-003Jan 6  - Immutep Ltd IMM.AX:IMMUTEP LTD: PATIENT ENROLMENT COMPLETED FOR INSIGHT-003IMMUTEP LTD: DATA UPDATES FROM INSIGHT-003 ARE EXPECTED IN 2025 AND BEYONDSource text: nGNX4w3z4tFurther company coverage: IMM.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O21K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2501390232","title":"Immutep Ltd: Data Updates From Insight-003 Are Expected in 2025 and Beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2501390232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501390232?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:14","pubTimestamp":1736169242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O21K0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2501239073","title":"Immutep Ltd: Patient Enrolment Completed for Insight-003","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239073?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:14","pubTimestamp":1736169242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O21K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2501972239","title":"Patient Enrolment Completed for INSIGHT-003","url":"https://stock-news.laohu8.com/highlight/detail?id=2501972239","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501972239?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable patients. Data updates from INSIGHT-003 are expected in 2025 and beyond. SYDNEY, AUSTRALIA, Jan. 06, 2025  -- Immutep Limited  , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that patient enrolment has been completed in the investigator-initiated INSIGHT-003 trial. INSIGHT-003 is evaluating eftilagimod alpha  in combination with the anti-PD-1 therapy, KEYTRUDA  and doublet chemotherapy as first line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer .About ImmutepImmutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/patient-enrolment-completed-insight-003-130000028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1116320901.HKD","LU0234572021.USD","LU0965509101.SGD","SG9999001176.SGD","IMM.AU","LU0058720904.USD","IE00BSNM7G36.USD","SG9999014567.USD","LU1941712264.USD","IMMP","LU0289739699.SGD","BK4534","BK4550","INAQU","BK4139","LU1291159041.SGD","SG9999013999.USD","LU0122379950.USD","LU2112291526.USD","LU1066051498.USD","MRK","IE00BLSP4452.SGD","LU0208291251.USD","BK4559","IE000M9KFDE8.USD","BK4516","SG9999015341.SGD","SG9999001176.USD","LU1093756168.USD","LU2106854487.HKD","LU1037948541.HKD","LU1941712348.USD","LU2461242641.AUD","LU1989772840.SGD","LU1585245621.USD","LU1066053197.SGD","LU2023250504.SGD","LU0965509010.AUD","LU0106261372.USD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","LU1934455277.USD","LU0861579265.USD","LU2324357040.USD","LU2361045086.USD","IE00BJT1NW94.SGD","LU1066051811.HKD","LU0265550946.USD","BK4588"],"gpt_icon":0},{"id":"2501428629","title":"Immutep Reaches Enrollment Target for Non-Small Cell Lung Cancer Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2501428629","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501428629?lang=en_us&edition=fundamental","pubTime":"2025-01-06 07:39","pubTimestamp":1736120362,"startTime":"0","endTime":"0","summary":"Immutep  said the phase 1 INSIGHT-003 trial reached an enrollment target of about 50 patients across Germany, according to a Monday Australian bourse filing.INSIGHT-003  is an investigator-initiated study led by the Frankfurt Institute of Clinical Cancer Research IKF evaluating a triple combination therapy in first-line non-small cell lung cancer patients.It is testing eftilagimod alpha in combination with antiPD-1 therapy, pembrolizumab, and doublet chemotherapy as a potential first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer.The biotechnology firm said that the first overall survival results, issued on Nov. 14, 2024, from the trial showed mature data in patients with a minimum follow-up of 22 months achieved a median overall survival of 32.9 months and a 24-month overall survival rate of 81%.The company's shares rose past 1% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2492291950","title":"BRIEF-Immutep Announces Initial Safety Data From First-In-Human Phase I Trial Evaluating IMP761","url":"https://stock-news.laohu8.com/highlight/detail?id=2492291950","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492291950?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:06","pubTimestamp":1734444396,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Announces Initial Safety Data From First-In-Human Phase I Trial Evaluating IMP761Dec 17 (Reuters) - Immutep Ltd IMM.AX:IMMUTEP ANNOUNCES INITIAL SAFETY DATA FROM FIRST-IN-HUMAN PHASE I T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA4QQP8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":55,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[]}}